Implant Sciences
This article was originally published in The Gray Sheet
Executive Summary
Brachytherapy firm hopes to receive 510(k) clearance by year-end for its ytterbium-169 breast cancer treatment. The company expects to receive a NIH grant within weeks to "fabricate a prototype treatment for performing this procedure and to measure the radiation dose pattern," according to a release. Ytterbium-169 could potentially replace post-lumpectomy breast cancer treatment involving external beam therapy or brachytherapy with higher-energy iridium-192...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.